EIB Global and World Health Organization Commit €10 Million to Revitalize Lebanon Healthcare Infrastructure and Chronic Disease Support

On March 6, 2025, a significant milestone in international humanitarian aid and public health development was achieved at the European Investment Bank Group Forum in Luxembourg. Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), alongside Thomas Östros, Vice-President of the European Investment Bank (EIB Global), formally signed a landmark agreement committing a €10 million grant toward the urgent reinforcement of Lebanon’s fragile public health infrastructure. This financial infusion arrives at a critical juncture for the Mediterranean nation, which has spent years navigating compounding socioeconomic collapses, institutional paralysis, and geopolitical instability.

The primary objectives of this newly minted partnership are twofold: to completely rebuild and modernize Lebanon’s Central Public Health Laboratory—a foundational pillar of national disease surveillance and epidemiological safety—and to deliver uninterrupted medical supplies and specialized healthcare support to more than 50,000 vulnerable individuals suffering from chronic and life-threatening conditions such as diabetes, cardiovascular diseases, and various forms of cancer. By targeting these specific domains, the initiative seeks to bridge critical gaps in the national healthcare continuum, offering a lifeline to patients who have been disproportionately affected by medication shortages and skyrocketing treatment costs.

Main Facts of the Agreement

The €10 million grant is structured to address systemic vulnerabilities that have crippled Lebanon’s health sector over the past half-decade. At the core of the agreement is the reconstruction and operational re-establishment of the Central Public Health Laboratory. This facility is not merely a brick-and-mortar building; it is the ultimate national reference center responsible for disease detection, microbiological surveillance, antimicrobial resistance tracking, and the quality control of imported and locally manufactured pharmaceuticals. Without a functioning central laboratory, health authorities operate largely in the dark during disease outbreaks, unable to effectively sequence pathogens or guarantee the safety of consumables entering the market.

In parallel with laboratory reconstruction, a substantial portion of the funding is earmarked for direct clinical intervention. The initiative prioritizes the uninterrupted procurement and distribution of essential medicines for non-communicable diseases (NCDs). In recent years, Lebanon’s financial crisis has led to the lifting of state subsidies on many essential drugs, pushing life-saving medications for hypertension, diabetes, and oncology out of reach for a vast majority of the population. By explicitly targeting over 50,000 patients living with these chronic conditions, the WHO and EIB Global intervention aims to avert preventable mortality, reduce catastrophic out-of-pocket health expenditures for impoverished households, and alleviate the crushing burden on secondary and tertiary care hospitals.

Background Context: The Anatomy of Lebanon’s Healthcare Crisis

To fully appreciate the magnitude and urgency of the EIB Global and WHO partnership, one must examine the cascading crises that have systematically dismantled Lebanon’s once-touted healthcare system. Historically, Lebanon was regarded as the medical hub of the Middle East, boasting advanced private and public hospitals, highly trained medical professionals, and a robust pharmaceutical sector that attracted patients from across the region. However, this reputation masked structural vulnerabilities that were violently exposed starting in late 2019.

The convergence of a severe economic and financial meltdown—characterized by the collapse of the national currency, hyperinflation, and the informal freezing of bank deposits—ignited a downward spiral. The Lebanese pound lost more than 98 percent of its value against the US dollar, wiping out the purchasing power of citizens and the operational budgets of public institutions alike. Hospitals and clinics found themselves unable to secure foreign currency to import vital medical equipment, spare parts, and medications.

Compounding this economic disaster was the catastrophic August 4, 2020, Beirut Port explosion, which severely damaged or destroyed numerous healthcare facilities in the capital, including major hospitals and pharmaceutical warehouses. The blast dealt a psychological and physical blow to an already buckling medical infrastructure. Furthermore, the COVID-19 pandemic stretched remaining resources to their absolute limits, followed rapidly by a massive resurgence of cholera in 2022—the first outbreak in the country in nearly three decades—which highlighted the dangerous degradation of public sanitation and epidemiological monitoring capabilities.

Compounding these domestic strains has been the protracted regional displacement crisis. Lebanon hosts the highest per capita concentration of refugees in the world, including hundreds of thousands of displaced Syrians. The influx of vulnerable populations placed an unprecedented strain on public hospitals, primary healthcare centers, and subsidization programs, exhausting the state’s fiscal capacity long before the economic crash fully materialized.

Chronology of Events Leading to the March 2025 Agreement

The path toward the March 6, 2025, signing ceremony in Luxembourg has been marked by incremental, targeted international interventions aimed at keeping Lebanon’s health system on life support.

In late 2019 and throughout 2020, as the financial crisis took root, the WHO, alongside international donors and partner agencies, shifted from a development posture to emergency humanitarian response mode. Efforts were concentrated on emergency supply chains, distributing emergency trauma kits, and supplying personal protective equipment during the peak of the pandemic.

By 2021 and 2022, the Lebanese Ministry of Public Health, working closely with the WHO and the World Bank, attempted to manage dwindling foreign exchange reserves by gradually rationalizing medicine subsidies. This painful transition led to frequent nationwide shortages of cancer therapies, insulin, and cardiovascular medications, sparking public outcry and forcing patients to rely heavily on erratic donations or dangerous black-market alternatives.

In 2023, international financial institutions and European development banks began exploring more durable, structural interventions to transition Lebanon away from perpetual emergency triage. Discussions between the European Investment Bank—the lending arm of the European Union—and the World Health Organization intensified, focusing on how to combine the EIB’s financial engineering and capital deployment capacity with the WHO’s deep technical expertise and on-the-ground operational networks in Lebanon.

Throughout 2024, preliminary assessments for the rehabilitation of the Central Public Health Laboratory were conducted. Stakeholders mapped out the technical requirements for modernizing the facility to meet international biosafety standards. Simultaneously, data collection exercises identified the most pressing pharmaceutical supply chain bottlenecks, ensuring that any future financial commitment would directly target the demographic groups most at risk of treatment interruption.

The culmination of these collaborative efforts materialized on March 6, 2025, at the EIB Group Forum in Luxembourg. The formal signing by Dr. Tedros Adhanom Ghebreyesus and Thomas Östros codified months of technical negotiations into a concrete €10 million grant, establishing a formal framework for implementation throughout the subsequent budgetary cycles.

Supporting Data and Demographic Realities

The urgency of the EIB Global and WHO initiative is underscored by sobering public health data concerning Lebanon’s demographic and epidemiological landscape. Non-communicable diseases account for the vast majority of mortality in Lebanon, mirroring global epidemiological shifts but amplified by the stress of chronic socioeconomic deprivation.

According to global health assessments, cardiovascular diseases alone are responsible for nearly 40 percent of all deaths in the country, while cancer rates have climbed steadily over the past two decades. Diabetes prevalence among adults has also risen, requiring continuous, uninterrupted pharmacological management to prevent debilitating complications such as renal failure, blindness, and cardiovascular events. Prior to the economic collapse, the Lebanese Ministry of Public Health subsidized these treatments heavily. However, by 2023, studies indicated that over 70 percent of households reported difficulties in accessing required medications due to prohibitive costs, forcing countless patients to ration doses, skip treatments entirely, or abandon therapies altogether.

On the epidemiological front, the Central Public Health Laboratory served historically as the sentinel site for national health security. Before its operational capacity was severely degraded by resource shortages, power outages, and infrastructural decay, the laboratory processed tens of thousands of diagnostic samples annually. It monitored antimicrobial resistance patterns across Lebanese hospitals—a critical global health threat—and served as the definitive verification point for food safety and environmental health. The re-establishment of this laboratory under the new grant is expected to restore critical surveillance nodes, allowing health authorities to detect emerging infectious disease threats before they cascade into national or regional crises.

Official Responses and Institutional Perspectives

While the formal agreement was signed by high-ranking officials in Luxembourg, the ripple effects of the announcement resonated across international health bodies and diplomatic channels.

Speaking at the EIB Group Forum, WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasized the existential nature of the support. He noted that health is a fundamental human right that cannot be treated as a secondary concern during economic crises. Dr. Tedros underscored that international solidarity is essential to prevent the total collapse of health systems in fragile settings, warning that a failure to support Lebanon’s primary healthcare and laboratory infrastructure would have profound regional and global security implications, particularly concerning infectious disease surveillance and population displacement.

Representing the European Investment Bank, Vice-President Thomas Östros highlighted EIB Global’s strategic commitment to fostering resilience in neighboring regions. Östros remarked that sustainable economic recovery is impossible without a healthy, functioning population. He pointed out that the partnership with the WHO ensures that European taxpayer funds are channeled through trusted, highly competent multilateral networks capable of delivering transparent, efficient, and impactful results on the ground. EIB Global, the specialized arm of the EIB group dedicated to operations outside the European Union, views this investment as part of its broader mandate to support sustainable development, climate resilience, and social infrastructure in the Mediterranean neighborhood.

Local health advocates and international humanitarian organizations inside Lebanon have also welcomed the announcement, noting that while €10 million cannot single-handedly solve the structural deficit of the national health budget, it provides a highly targeted, strategic intervention where it is needed most. Medical professionals on the ground have frequently stressed that chronic disease management and diagnostic laboratory capabilities are the two areas that suffered the most profound systemic decay, making the chosen focus of the grant both timely and clinically appropriate.

Broader Impact and Strategic Implications

The €10 million grant from EIB Global to the WHO for Lebanon carries implications that extend far beyond the immediate procurement of drugs and the refurbishment of a single laboratory.

First and foremost, the initiative represents a vital model of institutional burden-sharing between international financial institutions and specialized United Nations agencies. Historically, development banks focused primarily on large-scale infrastructure projects—such as roads, water treatment plants, and energy grids—while humanitarian agencies managed immediate health crises. The convergence of EIB Global’s financial leverage with WHO’s normative and technical health leadership points toward a more integrated, nexus-oriented approach to crisis management, bridging the artificial divide between emergency relief and long-term development.

Second, the restoration of the Central Public Health Laboratory has significant regional biosecurity implications. In an interconnected world, disease vectors do not respect national borders. The resurgence of cholera in Lebanon in recent years served as a stark reminder that compromised public health infrastructure in one nation poses a direct epidemiological threat to the wider Middle East and the European Union’s southern borders. By rebuilding Lebanon’s national reference laboratory, the international community is investing in regional health security, ensuring that pathogens can be identified, tracked, and contained rapidly at their source.

Third, the targeted support for 50,000 chronic disease patients addresses a profound humanitarian imperative while simultaneously relieving pressure on Lebanon’s tertiary hospital sector. When patients with chronic conditions lack access to affordable medication, their diseases inevitably progress to acute, emergency stages requiring expensive hospitalization, intensive care unit admission, and complex surgical interventions. By subsidizing outpatient chronic care and ensuring a reliable pharmaceutical supply chain, the initiative prevents avoidable hospitalizations, thereby conserving scarce medical resources and reducing the financial strain on both the state and afflicted families.

Looking Ahead: Implementation and Accountability

As the agreement moves from the signing table in Luxembourg to operational execution in Beirut, attention will naturally turn to implementation timelines, transparency, and monitoring mechanisms. Both the WHO and EIB Global have established rigorous oversight frameworks to ensure that the €10 million grant is utilized with maximum efficiency and accountability.

Procurement processes for pharmaceutical supplies will be managed through established WHO international channels, mitigating the risk of supply chain corruption and ensuring that medications meet stringent international quality standards before reaching Lebanese clinics. Concurrently, engineering and procurement contracts for the Central Public Health Laboratory will adhere to transparent bidding standards, with physical rehabilitation works monitored closely by technical experts from both institutions.

Ultimately, while the challenges facing Lebanon remain vast and deeply entrenched, the March 6, 2025 agreement stands as a testament to the power of sustained international cooperation. By securing the foundations of national disease surveillance and providing a tangible lifeline to tens of thousands of vulnerable chronic disease sufferers, EIB Global and the World Health Organization have laid a critical stepping stone toward the long-term recovery and resilience of Lebanon’s public health sector.